Recurrence rate after a first venous thrombosis in patients with familial thrombophilia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 9, 2005, Pages 1992-1997

  Vossen, Carla Y ^a   Walker, Isobel D ^b   Svensson, Peter ^c   Souto, Juan C ^d   Scharrer, Inge ^e   Preston, F Eric ^f   Palareti, Gualtiero ^g   Pabinger, Ingrid ^h   Van Der Meer, Felix J M ^a   Makris, Mike ^f   Fontcuberta, Jordi ^d   Conard, Jacqueline ⁱ   Rosendaal, Frits R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF VIENNA   (Austria)

ⁱ HÔTEL DIEU   (France)

Author keywords

Familial thrombophilia; Incidence; Prospective follow up; Recurrence; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C; PROTEIN S;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; ARTICLE; BLEEDING; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECURRENCE RISK; THROMBOPHILIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; CHILD; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SEX DISTRIBUTION; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 24144492688     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000174806.76629.7b     Document Type: Article

References (29)

1. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
2. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160: 761-768.
3. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-774.
4. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med. 1995;155:1031-1037.
5. Holmström M, Åberg W, Lockner D, Paul C. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis. Thromb Haemost. 1999;82:1222-1226.
6. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors and recurrent venous thrombosis: 12 years prospective follow-up in the Leiden Thrombophilia Study (LETS). JAMA. 2005;293:2352-2361.
7. Lensen RP, Rosendaal FR, Koster T, Allaart CF, de Ronde H, Vandenbroucke JP, Reitsma PH, Bertina RM. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood. 1996;88:4205-4208.
8. Lensen RP, Bertina RM, de Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost. 2000;83:817-821.
9. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol. 1996;16: 742-748.
10. Van den Belt AG, Sanson BJ, Simioni P, Prandoni P, Büller HR, Girolami A, Prins MH. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997;157:2227-2232.
11. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, and Leone G. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806.
12. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost. 1999;81: 684-689.
13. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
14. Simioni P, Prandoni P, Lensing AW, Manfrin D, Tormene D, Gavasso S, Girolami B, Sardella C, Prins M. Girolami A. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000;96:3329-3333.
15. Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, Schönauer V, Lechner K, Kyrle PA. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med. 2002; 162:2357-2360.
16. Meinardi JR, Middeldorp S, de Kam PJ, Koopman MMW, van Pampus ECM, Hamulyák K, Prins MH, Büller HR, van der Meer J. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol. 2002; 116:625-631.
17. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJ, Pabinger I, Palareti G, Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost. 2004;2:1526-1532.
18. Wissenschaftliche Tabellen Geigy, Teilband Statistik, 8. Auflage, Basel; 1980:152.
19. Kurtzke JF. On estimating survival; a tale of two censors. J Clin Epidemiol. 1989;42:169-175.
20. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet. 2000;356:182-183.
21. Margaglione M, Brancaccio V, De Lucia D, Martinelli I, Ciampa A, Grandone E, Di Minno G. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest. 2000;118:1405-1411.
22. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558-2563.
23. Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost. 2004;2: 2152-2155.
24. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg G, Walter H, Viering S, Nordlander S, Leijd B, Jönsson KA, Hjorth M, Linder O, Boberg J. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332:1661-1665.
25. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-611.
26. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Biossel JP. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103: 2453-2460.
27. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. l994;72:352-358.
28. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993;153:1557-1562.
29. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423-428.